此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Tiragolumab 联合 Atezolizumab 与安慰剂联合 Atezolizumab 治疗既往未治疗的局部晚期不可切除或转移性 PD-L1 选择的非小细胞肺癌患者的研究 (SKYSCRAPER-01)

2026年11月6日 更新者:Hoffmann-La Roche

抗 Tigit 抗体 Tiragolumab 联合 Atezolizumab 与安慰剂联合 Atezolizumab 在既往未治疗的局部晚期不可切除或转移性 PD-L1 选择非-小细胞肺癌

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.

研究概览

研究类型

介入性

注册 (实际的)

620

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Beijing、中国、100142
        • Beijing Cancer Hospital
      • Changchun、中国、130021
        • The First Hospital of Jilin University
      • Chengdu、中国、610041
        • West China Hospital, Sichuan University
      • Chongqing、中国、400030
        • Chongqing Cancer Hospital
      • Fuzhou、中国、350014
        • Fujian Cancer Hospital
      • Haikou、中国、570311
        • Hainan General Hospital
      • Hangzhou、中国、310016
        • Sir Run Run Shaw Hospital Zhejiang University
      • Harbin、中国、150081
        • Harbin Medical University Cancer Hospital
      • Jinan、中国、250013
        • Jinan Central Hospital
      • Meizhou、中国、514031
        • Meizhou People's Hospital
      • Nanchang、中国、330200
        • The 1st Affiliated Hospital of Nanchang Unversity
      • Nantong、中国、226361
        • Nantong Tumor Hospital
      • Shanghai、中国、200433
        • Shanghai Pulmonary Hospital
      • Shanghai、中国、200032
        • Zhongshan Hospital Fudan University
      • Shanghai、中国、200120
        • Fudan University Shanghai Cancer Center
      • Wuhan、中国、430022
        • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
      • Xi'an、中国、710061
        • First Affiliated Hospital of Medical College of Xi'an Jiaotong University
      • Zhejiang、中国、310022
        • Zhejiang Cancer Hospital
      • Kryvyi Rih、乌克兰、50048
        • ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council
      • Uzhhorod、乌克兰、88000
        • Uzhgorod Nat. University Central Municip Hosp
    • Moscow Oblast
      • Moscow、Moscow Oblast、俄罗斯、143422
        • MEDSI Clinical Hospital on Pyatnitsky Highway
      • Moscow、Moscow Oblast、俄罗斯、105229
        • Main Military Clinical Hospital named after N.N. Burdenko
    • Sankt-Peterburg
      • Saint Petersburg、Sankt-Peterburg、俄罗斯、194291
        • Leningrad Regional Clinical Hospital
      • Saint Petersburg、Sankt-Peterburg、俄罗斯、189646
        • Institute of Oncology
      • Saint Petersburg、Sankt-Peterburg、俄罗斯、197089
        • St. Petersburg Med Univ
      • Saint Petersburg、Sankt-Peterburg、俄罗斯、197758
        • St. Petersburg Clinical Scientific Center of special services medical assis (oncology)
      • Budapest、匈牙利、1121
        • Orszagos Koranyi TBC es Pulmonologiai Intezet
      • Mátraháza、匈牙利、3233
        • Matrai Gyogyintezet
      • Szolnok、匈牙利、5004
        • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház
      • Guishan Dist.、台湾、33305
        • Chang Gung Memorial Hospital - Linkou Branch
      • Kaohsiung City、台湾、83301
        • Kaohsiung Chang Gung Memorial Hospital
      • Kaohsiung City、台湾、807
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • New Taipei City、台湾、23561
        • Taipei Medical University ?Shuang Ho Hospital
      • Taichung、台湾、407
        • Taichung Veterans General Hospital
      • Tainan、台湾、704
        • National Cheng Kung Uni Hospital
      • Taipei、台湾、112
        • Taipei Veterans General Hospital
      • Zhongzheng Dist.、台湾、10048
        • National Taiwan University Hospital
      • Adana、土耳其(türkiye)、01120
        • Adana Baskent University Hospital
      • Ankara、土耳其(türkiye)、06100
        • Hacettepe University Medical Faculty
      • Istanbul、土耳其(türkiye)、34098
        • Istanbul University Cerrahpasa Faculty of Medicine
      • Izmir、土耳其(türkiye)、35110
        • Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
      • Kadiköy、土耳其(türkiye)、34722
        • Goztepe Prof.Dr. Suleyman Yalcin City Hospital
      • Malatya、土耳其(türkiye)、44280
        • Inonu University Medical Faculty of Medicine
      • Belgrade、塞尔维亚、11000
        • Clinical Center of Serbia
      • Belgrade、塞尔维亚、11080
        • University Hospital Medical Center Bezanijska kosa
    • Mexico CITY (federal District)
      • México、Mexico CITY (federal District)、墨西哥、06100
        • Cryptex Investigacion Clinica SA de CV
    • Nuevo León
      • Monterrey、Nuevo León、墨西哥、64710
        • AVIX Investigación Clínica S.C
    • Querétaro
      • Querétaro City、Querétaro、墨西哥、76000
        • Cuidados oncologicos
      • Linz、奥地利、4020
        • Ordensklinikum Linz Elisabethinen
      • Vienna、奥地利、1140
        • Klinik Penzing
      • Vienna、奥地利、1210
        • Krankenhaus Nord - Klinik Floridsdorf
    • Rio Grande do Sul
      • Ijuí、Rio Grande do Sul、巴西、98700-000
        • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
    • São Paulo
      • Barretos、São Paulo、巴西、14784-400
        • Hospital de Cancer de Barretos
      • Athens、希腊、185 47
        • Metropolitan Hospital
      • Athens、希腊、104 31
        • Sotiria Hospital
      • Larissa、希腊、411 10
        • University Hospital of Larissa
      • Thessaloniki、希腊、570 01
        • Diavalkaniko Hospital
      • Frankfurt、德国、60488
        • Krankenhaus Nordwest
      • Großhansdorf、德国、22927
        • LungenClinic Großhansdorf GmbH
      • Halle、德国、06120
        • Krankenhaus Martha-Maria Halle-Doelau gGmbH
      • Immenhausen、德国、34376
        • Fachklinik für Lungenerkrankungen
      • Löwenstein、德国、74245
        • SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein
      • Münster、德国、48153
        • Gemeinschaftspraxis für Hämatologie und Onkologie
      • Stuttgart、德国、70376
        • Klinik Schillerhöhe
    • Campania
      • Naples、Campania、意大利、80131
        • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
    • Lazio
      • Rome、Lazio、意大利、00151
        • Azienda Ospedaliera San Camillo Forlanini
      • Rome、Lazio、意大利、00168
        • Policlinico Universitario "Agostino Gemelli"
    • Lombardy
      • Milan、Lombardy、意大利、20141
        • Irccs Istituto Europeo di Oncologia (IEO)
      • Monza、Lombardy、意大利、20900
        • Asst Di Monza
      • Rozzano、Lombardy、意大利、20089
        • Istituto Clinico Humanitas
    • Piedmont
      • Orbassano、Piedmont、意大利、10043
        • Azienda Sanitaria Ospedaliera S Luigi Gonzaga
    • Umbria
      • Perugia、Umbria、意大利、06156
        • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
    • Veneto
      • Padova、Veneto、意大利、35128
        • IOV - Istituto Oncologico Veneto - IRCCS
      • Aichi、日本、464-8681
        • Aichi Cancer Center
      • Chiba、日本、277-8577
        • National Cancer Center Hospital East
      • Fukuoka、日本、812-8582
        • Kyushu University Hospital
      • Miyagi、日本、980-0873
        • Sendai Kousei Hospital
      • Niigata、日本、951-8566
        • Niigata Cancer Center Hospital
      • Osaka、日本、589-8511
        • Kindai University Hospital
      • Osaka、日本、541-8567
        • Osaka International Cancer Institute
      • Saitama、日本、362-0806
        • Saitama Cancer Center
      • Sakaishi、日本、591-8555
        • NHO Kinki-Chuo Chest Medical Center
      • Shizuoka、日本、411-8777
        • Shizuoka Cancer Center
      • Tokyo、日本、104-0045
        • National Cancer Center Hospital
      • Tokyo、日本、135-8550
        • The Cancer Institute Hospital of JFCR
      • Gda?sk、波兰、80-214
        • Uniwersyteckie Centrum Kliniczne
      • Olsztyn、波兰、10-357
        • Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
      • Poznan、波兰、60-569
        • Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
      • Bangkok、泰国、10330
        • Chulalongkorn Hospital
      • Bangkok、泰国、10400
        • Ramathibodi Hospital
      • Bangkok、泰国、10700
        • Faculty of Med. Siriraj Hosp.
      • Songkhla、泰国、90110
        • Songklanagarind Hospital
    • Queensland
      • Woolloongabba、Queensland、澳大利亚、4102
        • Princess Alexandra Hospital
    • Victoria
      • Heidelberg、Victoria、澳大利亚、3084
        • Austin Hospital Olivia Newton John Cancer Centre
      • Melbourne、Victoria、澳大利亚、3000
        • Peter Maccallum Cancer Centre
      • Bern、瑞士、3010
        • Inselspital Bern
      • Lausanne、瑞士、1011
        • CHUV
      • Sankt Gallen、瑞士、9000
        • HOCH Health Ostschweiz, Kantonsspital St. Gallen
      • Arequipa、秘鲁、5154
        • Instituto Regional de Enfermedades Neoplásicas del Sur
      • Lima、秘鲁、15038
        • Instituto Nacional de Enfermedades Neoplasicas
      • Lima、秘鲁、Lima 41
        • Clinica Internacional, Sede San Borja
      • San Isidro、秘鲁、Lima 27
        • Clinica Ricardo Palma
    • Colorado
      • Denver、Colorado、美国、80220
        • Rocky Mountain Cancer Center - Denver
    • Connecticut
      • New Haven、Connecticut、美国、06520
        • Yale Cancer Center
    • Florida
      • St. Petersburg、Florida、美国、33705
        • SCRI Florida Cancer Specialists North
      • Tallahassee、Florida、美国、32308
        • SCRI Florida Cancer Specialists PAN
    • Minnesota
      • Saint Paul、Minnesota、美国、55102
        • US oncology research at Minnesota Oncology
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • SCRI Oncology Partners
    • Virginia
      • Fairfax、Virginia、美国、22031
        • Virginia Cancer Specialists (Fairfax) - USOR
      • Salem、Virginia、美国、24153
        • Onc & Hem Assoc SW Virginia
      • 's-Hertogenbosch、荷兰、5223 GZ
        • Jeroen Bosch Ziekenhuis
      • Ede、荷兰、6716 RP
        • Ziekenhuis Gelderse Vallei
      • Leeuwarden、荷兰、8934 AD
        • Frisius MC Leeuwarden
      • The Hague、荷兰、2545 AA
        • Hagaziekenhuis, locatie Leyweg
      • Madrid、西班牙、28041
        • Hospital 12 de Octubre
      • Madrid、西班牙、28222
        • Hospital Universitario Puerta de Hierro - Majadahonda
      • Madrid、西班牙、41013
        • Hospital Universitario Virgen del Rocío
      • Málaga、西班牙、29010
        • Hospital Regional Universitario de Malaga
      • Zaragoza、西班牙、50009
        • Hosp Clinico Univ Lozano Blesa
    • Barcelona
      • Badalona、Barcelona、西班牙、08916
        • Hospital Universitario Germans Trias i Pujol
      • Cheongju-si、韩国、28644
        • Chungbuk National University Hospital
      • Gyeonggi-do、韩国、13620
        • Seoul National University Bundang Hospital
      • Gyeonggi-do、韩国、16499
        • Ajou University Medical Center
      • Incheon、韩国、21565
        • Gachon University Gil Medical Center
      • Jeollanam-do、韩国、58128
        • Chonnam National University Hwasun Hospital
      • Seoul、韩国、03080
        • Seoul National University Hospital
      • Seoul、韩国、05505
        • Asan Medical Center
      • Seoul、韩国、03722
        • Severance Hospital, Yonsei University Health System
      • Seoul、韩国、08308
        • Korea University Guro Hospital
      • Seoul、韩国、6351
        • Samsung Medical Center
      • Seoul、韩国、03181
        • Kangbuk Samsung Medical Center
      • Suwon、韩国、442-723
        • St. Vincent's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Histologically or cytologically documented locally advanced or recurrent NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic Stage IV non-squamous or squamous NSCLC
  • No prior systemic treatment for metastatic NSCLC
  • High tumor tissue PD-L1 expression
  • Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
  • Adequate hematologic and end-organ function
  • For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry.

Exclusion Criteria:

  • Known mutation in the EGFR gene or an ALK fusion oncogene
  • Symptomatic, untreated, or actively progressing central nervous system metastases
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
  • Malignancies other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Positive test result for human immunodeficiency virus (HIV)
  • Active hepatitis B or hepatitis C
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Tiragolumab + Atezolizumab

Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

其他名称:
  • 技术中心

Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.

其他名称:
  • MTIG7192A
安慰剂比较:Placebo + Atezolizumab

Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

其他名称:
  • 技术中心

Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)
大体时间:From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)

PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions. Kaplan-Meier (K-M) method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS
大体时间:From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)

PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Global Cohort: Overall Survival (OS) in the PAS
大体时间:From randomization to death from any cause (up to approximately 54.7 months)

OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 54.7 months)
China Cohort: OS in the PAS
大体时间:From randomization to death from any cause (up to approximately 49.1 months)

OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 49.1 months)
Global Cohort: Number of Participants With Adverse Events (AEs)
大体时间:Up to 65.1 months

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to 65.1 months
China Cohort: Number of Participants With AEs
大体时间:Up to 49.3 months

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to 49.3 months
Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale
大体时间:Up to 65.1 months

CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

Up to 65.1 months
China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale
大体时间:Up to 49.3 months

CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

Up to 49.3 months

次要结果测量

结果测量
措施说明
大体时间
Global Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)
大体时间:From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)

PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
China Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS
大体时间:From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)

PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Global Cohort: OS in the SAS
大体时间:From randomization to death from any cause (up to approximately 54.7 months)

OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 54.7 months)
China Cohort: OS in the SAS
大体时间:From randomization to death from any cause (up to approximately 49.1 months)

OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 49.1 months)
Global Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS
大体时间:Up to approximately 54.6 months

Confirmed ORR was defined as the percentage of participants with a confirmed objective response (OR), characterized by either a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

Up to approximately 54.6 months
China Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS
大体时间:Up to 49.3 months

Confirmed ORR was defined as the percentage of participants with a confirmed OR, characterized by either a CR or a PR, on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

Up to 49.3 months
Global Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
大体时间:From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)

DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)
China Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
大体时间:From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)

DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
大体时间:At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
大体时间:At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
大体时间:At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
大体时间:At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
Global Cohort: OS Rate at 12 Months and 24 Months in the PAS
大体时间:At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
China Cohort: OS Rate at 12 Months and 24 Months in the PAS
大体时间:At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
Global Cohort: OS Rate at 12 Months and 24 Months in the SAS
大体时间:At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
China Cohort: OS Rate at 12 Months and 24 Months in the SAS
大体时间:At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
Global Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS
大体时间:Up to approximately 54.6 months

TTCD was defined as the time from randomization to first confirmed clinically meaningful deterioration (CCMD). EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), global health status (GHS)/quality-of-life (QoL), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 54.6 months
China Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PAS
大体时间:Up to approximately 49.3 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 49.3 months
Global Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
大体时间:Up to approximately 54.6 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better health-related quality-of-life (HRQoL). CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 54.6 months
China Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
大体时间:Up to approximately 49.3 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better HRQoL. CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 49.3 months
Global Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
大体时间:Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
China Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
大体时间:Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Global Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
大体时间:Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
China Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
大体时间:Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Global Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab
大体时间:Up to approximately 54.6 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 54.6 months
China Cohort: Number of Participants With ADAs to Tiragolumab
大体时间:Up to approximately 49.3 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 49.3 months
Global Cohort: Number of Participants With ADAs to Atezolizumab
大体时间:Up to approximately 54.6 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 54.6 months
China Cohort: Number of Participants With ADAs to Atezolizumab
大体时间:Up to approximately 49.3 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 49.3 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Trial、Hoffmann-La Roche

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年3月4日

初级完成 (实际的)

2025年12月30日

研究完成 (实际的)

2025年12月30日

研究注册日期

首次提交

2020年3月2日

首先提交符合 QC 标准的

2020年3月2日

首次发布 (实际的)

2020年3月4日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • GO41717
  • 2019-002925-31 (EudraCT编号)
  • 2019 (美国 NIH 拨款/合同)
  • 2022-502482-17-00 (克蒂斯)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅